Table 1

Patient characteristics and details of COVID-19

IDAge, sexANCA serotypeConcomitant immunosuppressant at the time of COVID-19Vaccination statusSpike antibody level*Prevailing
Days from induction treatment to COVID-19COVID-19 treatmentCOVID-19 severityOutcomeLong COVID
183FMPORTX3 mRNA doses during BCDPositiveOmicron165Nirmatrelvir/ritonavirMildResolvedNo
254FPR3RTX3 mRNA doses preceding BCDNTOmicron77Nirmatrelvir/ritonavirMildResolvedNo
371MPR3RTX2 mRNA doses preceding BCD,
1 mRNA dose after BCD
481MPR3RTX, CYC prednisone 15 mg3 mRNA doses preceding BCDNTOmicron55Remdesivir, dexamethasoneSevereDeathNo
558FMPORTX prednisone 5 mg2 mRNA doses preceding BCDNTOmicron123NoneMildResolvedNo
658FMPORTX3 mRNA doses preceding BCDPositiveOmicron108BebtelovimabMildResolvedNo
775MMPORTX2 mRNA doses preceding BCD,
1 mRNA dose after BCD
834MMPORTX3 mRNA doses preceding BCDNTOmicron67Nirmatrelvir/ritonavirMildResolvedNo
  • *Positive spike antibody levels preceding this episode of COVID-19 resulted from either vaccination or prior infection during peripheral B cell presence, or through prior receipt of tixagevimab/cilgavimab.

  • ANCA, antineutrophil cytoplasmic antibody; BCD, B cell depletion; CYC, cyclophosphamide; F, female; M, male; MPO, myeloperoxidase; mRNA, messenger RNA; NT, not tested; PR3, proteinase-3; RTX, rituximab.